Understanding Barrett's Esophagus: A Global Influencer
Prateek Sharma, MD, has dedicated his entire career to better understanding a specific complication that can arise from longstanding acid reflux, a condition now so common that people typically self-treat it with over-the-counter products.
Acid reflux symptoms include heartburn and acid regurgitation, and it affects approximately 15% of the adult population. One out of 10 adults with longstanding acid reflux can progress to a condition in which the normal tissue lining the esophagus, after constant exposure to acid from the stomach, changes to resemble the lining of the intestine.
Here is why Sharma has authored more than 350 papers about it: The condition, known as Barrett’s esophagus, is a precursor to a subtype of esophageal cancer. Called esophageal adenocarcinoma, this type of cancer is on the rise, and it comprises 80% of all esophageal cancer cases, up from 20% a few decades ago.
During the 1960s and 1970s, the esophageal cancer 5-year survival rate was only 5%. Thanks to advances in treatment and earlier detection, it’s now 20% with at least 25% of localized cancers being diagnosed. However, compared to localized breast cancer and colon cancer, which each have a 5-year survival rate exceeding 90%, there is more progress to be made.
Changing the treatment landscape
Sharma’s contributions to the understanding of Barrett’s esophagus have already shaped the way we diagnose and treat the disease. In fact, a physician treating a patient with Barrett’s esophagus in any part of the world is likely using some tool developed by Sharma and his team.
About 12 years ago, Sharma, along with international experts, developed a categorization system that has since been adopted worldwide. Called the Prague classification system and utilized during endoscopy, the process helps determine the extent of Barrett’s esophagus, allowing the physician to then manage accordingly. It has been shown that the increasing area occupied by Barrett’s disease is linked with a higher risk of cancer, so careful grading of the extent is critical.
Patients with Barrett’s esophagus receive endoscopies every 3 to 5 years to watch for early signs of cancer development. The earlier a suspicious area (dysplasia) in the esophagus is spotted, the better. Ergo, the better the tool, the better the detection of dysplasia. In 2013, Sharma led a pivotal study that identified the optimal method to identify early signs of cancer.
“In our multicenter trial, we identified endoscopy methods that provide sharper contrast and better images, highlighting the superficial vessels of the tissue. It’s like upgrading your standard television to a new HD or 4K TV,” Sharma says.
He then led a group of experts to devise a global nomenclature system for these findings, called the BING classification system.
In 2017, Sharma led an investigator-initiated study that evaluated a two-sided camera capsule. About the size of a large multivitamin, the patient swallows the capsule and pictures are taken as it moves down the esophagus. Another capsule-related effort with Massachusetts General Hospital and funded by the National Cancer Institute is studying the effectiveness of optical coherence tomography (OCT), which uses light waves to take cross-sectional pictures of the esophagus layers.
“An endoscopy requires IV and sedation, and it can be costly in terms of money and time. The beauty of these newer methods is they are quick and noninvasive,” Sharma says.
Another endoscopic therapy saves patients with either high-grade dysplasia or early cancer from a major surgery in which some or most of the diseased esophagus is removed via an incision in the chest or stomach. The mortality rate is very high – about 20-30%. Over the last 15 years, Sharma has been working to make this surgery less invasive by operating via an endoscope.
Prioritizing patients by risk is a crucial component of care. Most patients with Barrett’s esophagus do not progress to cancer; therefore it’s important to identify those at high risk versus low risk. Sharma is the architect behind the first system ever to categorize Barrett’s esophagus patients into risk-level groups.
Called PIB (Progression in Barrett’s) scoring, the system determines Barrett’s esophagus patients’ progression to high-grade dysplasia and cancer. Nearly 4,600 patients were enrolled in this 10-year, multicenter study. PIB factors in the extent of Barrett’s esophagus, health history, gender and if they have low-grade dysplasia.
We are in a time where we are gaining so much ground on other cancer types. I want to say we have done the same for esophageal cancer. –Prateek Sharma, MDGastroenterologist
Sharma adds that PIB will change the way Barrett’s esophagus patients are managed, including eliminating unnecessary, costly procedures for patients with low scores.
“People who receive low risks can sleep better at night knowing that their risk for developing this cancer is extremely low,” Sharma says. “On the flip side, we can identify the patients with high scores and treat them more aggressively.”
The list of Sharma’s contributions to Barrett’s esophagus goes on, and there are several more collaborations in the pipeline. For him, it is about gaining traction on this precancerous condition and ultimately reducing the incidence of esophageal cancer.
“We are in a time where we are gaining so much ground on other cancer types,” Sharma says. “I want to say we have done the same for esophageal cancer.”
Ask about our clinical trials.
Clinical trials can help you learn more about your options. Search clinical trials available at our cancer center. Call 913-945-7552 or email firstname.lastname@example.org.